RSLS, ReShape Lifesciences, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. On 11/12/2021 Anthony Vendetti from Maxim Group brokerage Reiterated the Buy Rating for RSLS with a price target of $8.00. That is more that 5X from the current price. Looking forward to...
- ReShape leader in weight loss market - FDA approved Lap-Band manufacturing moved to the US - eliminated debt overhang - ReShape Marketplace - digital health solution June 30, 2021: Cash and cash equivalents and restricted cash were $40.2 million. ReShape Market Cap only 50.061M Shares Outstanding 17.20M On 7/1/2021, Ben Haynor from Alliance Global Partners...
On 6/17/2021 Alliance Global Partners brokerage Boosted the Price Target for RSLS ReShape Lifesciences stock from $12.00 to $18.50! ReShape Lifesciences is America's premier weight-loss solutions company. The FDA-approved Lap-Band® program provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling...
#Reshape | $RSLS is probably THE BIGGEST SCAM in entire #NASDAQ! REALLY? Yes! If you trade this, you will probably LOSE ALL YOUR MONEY!